Portfolio
16
companies
Bioliberty
Bioliberty builds soft robotic gloves and digital therapy platforms for stroke rehabilitation.
Carcinotech
Carcinotech manufactures 3D printed tumours from cancer cells for oncology testing and research.
Chromacity
Chromacity designs and manufactures advanced ultrafast pulsed fibre lasers for scientific and industrial research.
ClinSpec Diagnostics
ClinSpec Diagnostics develops rapid liquid biopsies for early cancer detection.
ClinSpec Dx
ClinSpec Dx develops blood test technology for the early detection of cancer.
Concinnity Genetics
Concinnity Genetics builds artificial intelligence platforms to improve the safety of gene therapies.
Cumulus Oncology
Cumulus Oncology builds spin-out companies to accelerate the development of new cancer treatments.
Dxcover
Dxcover develops multiomic spectral analysis technology for early cancer detection.
EnsiliTech
EnsiliTech develops room temperature stabilisation technology for vaccines and biologics.
Nami Surgical
Nami Surgical develops miniaturised ultrasonic devices for robotic-assisted procedures.
Naturbeads
Naturbeads produces biodegradable plant-based microspheres to replace microplastics across manufacturing sectors.
Neupulse
Neupulse develops a non-drug wristband therapy to help manage Tourette syndrome.
RAB-Microfluidics
RAB-Microfluidics develops lab on a chip technology for oil lubrication analysis.
TaiSan
Solid-state sodium-ion battery developer for electric mobility.
Waire Health
Waire Health builds autonomous remote patient monitoring sensors for healthcare providers.
Wobble Genomics
Wobble Genomics develops a novel approach to RNA sequencing for biotechnology applications.
Andrew McNeill
Managing Partner
Andrew serves as managing partner at Eos Advisory and holds investor director roles at Cumulus Oncology and Clinspec Diagnostics Limited. His background includes chief executive and chair positions at Fixed Phage and Chromacity.
LinkedInMark Beaumont
Partner
Mark brings operating experience from roles at Envoy Group and Eos Advisory, alongside broadcasting and media experience.
LinkedInAndrew McNeil
Managing Partner
Ana Stewart
Partner
Ana is a partner at Eos Advisory and serves as chief entrepreneur for the Scottish Government. She also holds non-executive and board roles across investment, commerce, and sport.
LinkedInAndrew Durkie
Partner
Andrew is a partner at Eos Advisory and serves as a non-executive director for Naturbeads and Penrhos Bio. He previously led strategic projects and bulk annuities structuring at Scottish Widows.
LinkedInAnne Muir
Director of Portfolio
Anne brings portfolio management experience from Eos Advisory, alongside previous academic research and innovation roles at the University of Dundee.
LinkedInEos Advisory and Mercia Ventures led the round, which will fund pilot tests and relocation to a new Coventry facility.
"While we’ve kept our most exciting breakthroughs in stealth, this funding will help us enhance the performance of sodium-ion batteries and bring the benefits to a mainstream audience. Watch this space"
The Bristol based biotech startup secured £4.5m from Eos Advisory, Calculus Capital, and HERmesa to expand manufacturing and drive commercial validation.
"The founding team of EnsiliTech is not just a team of collaborators. There is deep respect between all members of the team… created as a result of aligned values, respect for each other’s personalities, diversity of thought and backgrounds…"
Eos Advisory led the Series A round alongside new and existing backers to fund international expansion and commercialisation.
"The Dxcover technology combines deep technical innovation with machine learning to radically change the diagnostic landscape. Over the last three years they have conclusively shown the accuracy and ease of use of their diagnostic test across multiple cancer indications. This is very much aligned with Eos’ approach to investing in innovation that has the potential to impact positively in people's lives. More recently the team at Dxcover have focused on building a world class international team on both sides of the Atlantic. This funding round is very much about commercialization in both the UK and the US."
The Edinburgh spinout will use the capital to launch new programmes and establish its operational footprint.
"We are so excited to be taking the next step in our spin-out journey and want to sincerely thank all the investors and supporters who have helped us make it happen. Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible. This commitment from our investors, building on the ongoing support from Scottish Enterprise, speaks to the potential they see in our work, and we look forward to using the funding to further develop our technology."
The Bath-based sustainable ingredients developer secured backing from Eos Advisory, Progress Tech Transfer, CDP Venture Capital, and Paragon Capital Management.
"Giovanna and her team are tackling one of the most urgent environmental challenges of our time, and we look forward to supporting Naturbeads through its next, exciting phase of commercialisation."
